RxDoctor Payments Data

Jenny Montes de Oca Pineda, MD

Family Medicine · Coral Gables, FLNPI 1154562155

Payments from drug & device makers

$1,574in general payments, 2019–2025

Across 51 payments — averaging $30.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$347
  • Abbott$344
  • Lilly USA, LLC$338
  • GSK$188
  • Insmed, Inc.$130
  • AbbVie$74
  • plus $152 from 8 others

What the payments were for

  • Food & beverage$1,56299%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,574 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$47,254
Medicare patients
109
Services billed
559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$55,457
BiktarvyBictegrav/Emtricit/Tenofov Ala11$49,927
FarxigaDapagliflozin Propanediol31$33,933
JardianceEmpagliflozin28$33,095
EliquisApixaban25$29,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$18,871
MounjaroTirzepatide13$15,553
LinzessLinaclotide11$10,769
SynthroidLevothyroxine Sodium55$4,533
Omega-3 Acid Ethyl Esters11$1,976
Atorvastatin Calcium204$1,962
Ibandronate Sodium52$1,822
Omeprazole81$1,354
Levothyroxine Sodium105$1,268
Rosuvastatin Calcium92$1,182

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$347$55,45751 claims
GSKTrelegy Ellipta$188$18,87126 claims
Lilly USA, LLCMounjaro$338$15,55313 claims
AbbVieLinzess, Synthroid$74$15,30366 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →